 GARDEN CITY, N.Y., Aug. 20, 2021 GLOBE NEWSWIRE -- Beyond Air, Inc. NASDAQ: XAIR, a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO gNO for the treatment of solid tumors, today announced the appointment of Douglas Larson as Chief Financial Officer, succeeding Douglas Beck effective September 1, 2021. Mr. Beck will remain a consultant to the Company and is expected to work closely with Mr. Larson and the Beyond Air leadership team to ensure a seamless transition of CFO responsibilities. 